Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologyDiseaseMelanoma, MalignantSubgroupBRAF V600E mutationBRAF V600K mutationBrain MetastasesmucosalICD10C44.-MeSHMelanomaSequenceCheckMate 067: NIVO1/IPIL3, Melanoma (PID711) -|- NIVO1/IPIL3 - NIVO240, Melanoma, Maint. (PID713)CheckMate 204: NIVO1/IPIL3, Melanoma with Brain Metastases (PID1205) -|- NIVO1/IPIL3 - NIVO240, Maint. (PID1206)CheckMate 511: NIVO3/IPIL1, Melanoma (PID647) -|- NIVO3/IPIL1 - NIVO480, Melanoma, Maint. (PID648)EORTC 18071: IPIL10, Melanoma, adj., A (PID887) -|- IPIL10, Melanoma, adj., B (PID889)IMMUNED: NIVO1/IPIL3, Melanoma, adj., C1-4 (PID1894) -|- NIVO240, C5-24 (PID1895)IMspire150: VEMU(960/720)/COBI60, Melanoma, C1 (PID2201) -|- ATEZ840/VEMU720/COBI60, C2+ (PID2202)IPIL3, Melanoma, adj., C1-4 (PID583) -|- IPIL3, Melanoma, adj., C5-8 (PID584)T-VEC1, Melanoma, C1 (PID1182) -|- T-VEC100, Melanoma, C2+ (PID1184)ChemotherapyChemo-substanceAtezolizumabBevacizumabBinimetinibCarboplatinCobimetinibDabrafenibDacarbazineEncorafenibIpilimumabLenvatinibNivolumabNivolumab-RelatlimabPaclitaxelPembrolizumabTalimogen LaherparepvecTrametinibVemurafenibChemo-substanceAtezolizumabBevacizumabBinimetinibCarboplatinCobimetinibDabrafenibDacarbazineEncorafenibIpilimumabLenvatinibNivolumabNivolumab-RelatlimabPaclitaxelPembrolizumabTalimogen LaherparepvecTrametinibVemurafenibChemo-substanceAtezolizumabBevacizumabBinimetinibCarboplatinCobimetinibDabrafenibDacarbazineEncorafenibIpilimumabLenvatinibNivolumabNivolumab-RelatlimabPaclitaxelPembrolizumabTalimogen LaherparepvecTrametinibVemurafenibChemo-substanceAtezolizumabBevacizumabBinimetinibCarboplatinCobimetinibDabrafenibDacarbazineEncorafenibIpilimumabLenvatinibNivolumabNivolumab-RelatlimabPaclitaxelPembrolizumabTalimogen LaherparepvecTrametinibVemurafenibNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronNo. Substances1246Protocol classificationTherapy classificationalternativecurrent standardIntensityhigh doseStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceneoadjuvant / adjuvantTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaBleedingCardiotoxicityColitisDiarrheaDyspneaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHepatotoxicityHyperglycemiaHyperkeratosisHypertensionHyperthyroidismHypophysitisHypothyroidismIncrease AminotransferasesIncrease in lipaseMucositisMyalgiasNauseaNeuropathyNeutropeniaPhotosensitivityPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureRetinopathyThrombocytopenia below 50 000/µlVisual DisturbancesVomiting only studiesPublicationAuthorAndtbacka RArance AChapman PDummer REggermont AEggermont A /Luke JGutzmer RHodi FLarkin JLebbé CLong GPatel SRibas ARobert CTarhini ATawbi HTawbi HAWeber JWeber JSYan XZimmer LDiseasefortgeschrittenes, nicht reserzierbares oder metastasiertes Melanom, Stadium IIIC oder IV, 2. und weitere Linien, ECOG 0-1fortgeschrittenes Melanom, mukosal, Stadium III/IV, nichtresezierbar, Erstlinie, ECOG 0-1Ipilimumab refraktäres Melanom, BRAF V600 positiv, ECOG 0-1Malignes Melanom, Stadium III-IV, Progress nach PD-1/PD-L1-Inhibitor Therapiemalignes Melanom, Stadium IIIa, IIIB oder IV, R0-Resektion, ECOG 0-1Malignes Melanom, Stadium IIIA-IIIC, R0-Resektion, ECOG 0-1Malignes Melanom, Stadium IV, nach OP oder Radiatio, ohne nachweisbare Resterkrankung, 18-80 Jahre, ECOG 0-1malignes Melanom mit Hirnmetastasen, ECOG 0-1malignes Melanom mit Hirnmetastasen ohne Strahlentherapie, ECOG 0-1Melanom, R0-Resektion, Stadium IIIA-C, BRAF-V600+, ECOG 0-1Melanom, Stadium IIB/IIC und IIIA-C, Metastasen in regionalen Lymphknoten, adjuvant, ECOG 0-1Melanom, Stadium IIIA-C, Metastasen in regionalen Lymphknoten, adjuvant, ECOG 0-1Melanom, Stadium IIIB-IIID oder oligometastatisch resektabel Stadium IV, ECOG 0-2metastasiertes Melanom, komplette Lymphadenektomie oder Resektion, Stadium IIIb, IIIc oder IV, Alter > 15 Jahre, ECOG 0-1nicht kurativ resezierbares Melanom, Stadium III-IV, Karnofsky Status >50nicht reserzierbares, fortgeschrittenes oder metastasiertes Melanom in der Erstlinie, ECOG 0-1nicht resezierbares, malignes Melanom, Stadium III-IV, ECOG 0-1nicht resezierbares Melanom, Stadium III-IV, Erstlinie, ECOG 0-1nichtresezierbares Melanom, Stadium IIIB oder IV, ECOG 0-1nicht resezierbares Melanom, Stadium IIIC oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1nicht resezierbares Melanom, Stadium III oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1Nicht resezierbares Melanom, Stadium III oder IV, Erstlinientherapie, BRAF V600 Mutation, ECOG 0-1Nicht resezierbares oder metastasiertes malignes Melanom, Stadium III/IV, ECOG 0-1nichtresezierbraes Melanom, Stadium III und IV, Zweitlinie nach Chemotherapie, ECOG 0-2Stadium III oder IV Melanom ohne BRAF Mutation, ECOG 0-1OriginCheckMate 067 Study, Dana-Faber Cancer Institute, Boston and Memorial Sloan Kettering Cancer Center, New YorkDana-Faber Cancer Institute, BostonDermatology CIC Departments, Saint-Louis Hospital, Paris, CheckMate 511 TrialDermatology Service, Gustave Roussy, Villejuif-Paris Sud, FranceDivision of Cancer Medicine, University of Texas, RELATIVITY-047 trialGustave Roussy Cancer Campus Grand Paris, Villejuif, France, EORTC 18071Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, FranceGustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, France, Keynote 716Hospital Clinic Barcelona and IDIBAPS, Barcelona, Spain, LEAP-004 trialHuntsman cancer institute, University of Utah, Salt Lake City, Utah, OPTIM trialLaura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, CheckMate 238 CollaboratorsMedizinische Hochschule Hannover, Hannover, Germany, IMspire150 trialMelanoma Institute Australia, University of Sydney, AustraliaMelanoma Institute Australia, University of Sydney, AustralienMemorial Sloan-Kettering Cancer Center, New YorkMemorial Sloan Kettering Cancer Center, New York, BRIM-3 studyMoffitt Cancer Center, Tampa, FL, USA, CheckMate 037North American Intergroup E1609Peking University Cancer Hospital and Institute, Beijing, ChinaRoyal Marsden Hospital, LondonUniversity Hospital Essen, Essen, Germany, IMMUNED trialUniversity Hospital Zürich Skin Cancer Center, COLUMBUS trialUniversity of California, Los Angeles, USA, KEYNOTE-002University of Texas M.D. Anderson Cancer CenterUniversity of Texas M.D. Anderson Cancer Center, Houston University of Texas M.D. Anderson Cancer Center, Houston, CheckMate 204Protocols in Revision 37 protocols foundProtocols under revision.Atezolizumab 840 / Vemurafenib 720 / Cobimetinib 60, Malignant Melanoma, Cycle 2+ (PID2202)Dabrafenib 150 / Trametinib 2, Malignant Melanoma (PID717)Dabrafenib 150 / Trametinib 2, Melanoma, adjuvant (PID56)Dacarbazine 1000, Malignant Melanoma (PID726)Encorafenib 450 / Binimetinib 45, Malignant Melanoma (PID1361)Ipilimumab 10, Malignant Melanoma, Adjuvant, Part A (PID887)Ipilimumab 10, Malignant Melanoma, Adjuvant, Part B (PID889)Ipilimumab 3, Malignant Melanoma (PID718)Ipilimumab 3, Malignant Melanoma, adjuvant, Cycle 1-4 (PID583)Ipilimumab 3, Malignant Melanoma, adjuvant, Cycle 5-8 (PID584)Lenvatinib 20 / Pembrolizumab 200, Melanoma (PID2254)Nivolumab - Relatlimab 640, Malignant Melanoma (PID2329)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Malignant Melanoma with Brain Metastases, maintenance (PID1206)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Malignant Melanoma, adjuvant, Cycle 5-24 (PID1895)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Melanoma, Malignant, maintenance (PID713)Nivolumab 1 / Ipilimumab 3, Malignant Melanoma (PID711)Nivolumab 1 / Ipilimumab 3, Malignant Melanoma with Brain Metastases (PID1205)Nivolumab 1 / Ipilimumab 3, Melanoma, Malignant, Adjuvant, cycle 1-4 (PID1894)Nivolumab 240, Malignant Melanoma, Adjuvant (PID1033)Nivolumab 240, Malignant Melanoma, First Line (PID712)Nivolumab 240, Melanoma, second line (PID629)Nivolumab 3 / Ipilimumab 1 - Nivolumab 480, Melanoma, Malignant, Maintenance (PID648)Nivolumab 3 / Ipilimumab 1, Malignant Melanoma (PID647)Nivolumab 480, Malignant Melanoma, Adjuvant (PID1411)Nivolumab 480, Malignant Melanoma, First Line (PID1136)Nivolumab 480, Malignant Melanoma, Second Line (PID1137)Paclitaxel 175 / Carboplatin 5 / Bevacizumab 5, Melanoma (PID2017)Pembrolizumab 200, Melanoma (PID597)Pembrolizumab 200, Melanoma, adjuvant (PID1154)Pembrolizumab 200, Melanoma, neoadjuvant/adjuvant (PID2303)Pembrolizumab 400, Melanoma (PID1250)Pembrolizumab 400, Melanoma, adjuvant (PID1251)Talimogen Laherparepvec 1, malignant Melanoma, cycle 1 (PID1182)Talimogen Laherparepvec 100, Malignant Melanoma, Cycle 2+ (PID1184)Vemurafenib (960/720) / Cobimetinib 60, Malignant Melanoma, Cycle 1 (PID2201)Vemurafenib 960 / Cobimetinib 60, Malignant Melanoma (PID716)Vemurafenib 960, Malignant Melanoma (PID715)
